Chi Young

1.1k total citations
20 papers, 289 citations indexed

About

Chi Young is a scholar working on Immunology, Oncology and Surgery. According to data from OpenAlex, Chi Young has authored 20 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Immunology, 9 papers in Oncology and 3 papers in Surgery. Recurrent topics in Chi Young's work include CAR-T cell therapy research (6 papers), Immune Cell Function and Interaction (3 papers) and Phagocytosis and Immune Regulation (3 papers). Chi Young is often cited by papers focused on CAR-T cell therapy research (6 papers), Immune Cell Function and Interaction (3 papers) and Phagocytosis and Immune Regulation (3 papers). Chi Young collaborates with scholars based in United States and United Kingdom. Chi Young's co-authors include Sonja Schrepfer, T. Deuse, Kathy White, Xiaomeng Hu, Esteban S. Masuda, Andrew J. Connolly, Richard H. Scheller, Mary Shen, Mark K. Bennett and Betty Huang and has published in prestigious journals such as The Lancet, Nature Communications and Blood.

In The Last Decade

Chi Young

18 papers receiving 272 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Chi Young United States 7 117 96 76 69 66 20 289
Andréa Alex Schiavo Belgium 11 232 2.0× 55 0.6× 56 0.7× 82 1.2× 120 1.8× 13 404
I‐Hua Liu United States 9 216 1.8× 87 0.9× 44 0.6× 23 0.3× 38 0.6× 13 357
Laura Panacchia Italy 7 202 1.7× 68 0.7× 52 0.7× 41 0.6× 55 0.8× 7 422
Chia-Jui Ku United States 9 156 1.3× 35 0.4× 93 1.2× 43 0.6× 45 0.7× 11 347
Marsha Pellegrino Italy 13 212 1.8× 169 1.8× 103 1.4× 75 1.1× 28 0.4× 19 409
Anabel José Spain 7 178 1.5× 69 0.7× 26 0.3× 131 1.9× 91 1.4× 10 337
Lydia Farack Israel 7 114 1.0× 58 0.6× 32 0.4× 99 1.4× 105 1.6× 11 256
Haiting Ma United States 8 190 1.6× 84 0.9× 32 0.4× 37 0.5× 45 0.7× 14 304
Jiaqi Wang China 10 132 1.1× 52 0.5× 47 0.6× 35 0.5× 33 0.5× 48 366
Eílis Foran Ireland 5 186 1.6× 91 0.9× 42 0.6× 31 0.4× 43 0.7× 5 359

Countries citing papers authored by Chi Young

Since Specialization
Citations

This map shows the geographic impact of Chi Young's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi Young with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi Young more than expected).

Fields of papers citing papers by Chi Young

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chi Young. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi Young. The network helps show where Chi Young may publish in the future.

Co-authorship network of co-authors of Chi Young

This figure shows the co-authorship network connecting the top 25 collaborators of Chi Young. A scholar is included among the top collaborators of Chi Young based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chi Young. Chi Young is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hu, Xiaomeng, Kathy White, Chenyan Wang, et al.. (2024). The HIP mouse and all of its organs are completely invisible to allogeneic immune cells. iScience. 28(1). 111492–111492. 3 indexed citations
2.
Hu, Xiaomeng, Kathy White, Chi Young, et al.. (2024). Hypoimmune islets achieve insulin independence after allogeneic transplantation in a fully immunocompetent non-human primate. Cell stem cell. 31(3). 334–340.e5. 29 indexed citations
3.
Hu, Xiaomeng, Kathy White, Eléonore Tham, et al.. (2023). Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. Nature Communications. 14(1). 2020–2020. 57 indexed citations
4.
Kinder, Jeremy M., Allison O’Rourke, Aaron Lampano, et al.. (2023). Development of a Novel, Allogeneic GPRC5D-Directed CAR for Treatment of Multiple Myeloma Patients. Blood. 142(Supplement 1). 3290–3290. 2 indexed citations
5.
Hu, Xiaomeng, Kathy White, Chi Young, et al.. (2023). Human hypoimmune primary pancreatic islets avoid rejection and autoimmunity and alleviate diabetes in allogeneic humanized mice. Science Translational Medicine. 15(691). eadg5794–eadg5794. 55 indexed citations
6.
Johnson, Adam, Xiaomeng Hu, Neal Van Hoeven, et al.. (2022). A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape. Blood. 140(Supplement 1). 4552–4553. 2 indexed citations
8.
Hu, Xiaomeng, Mo A. Dao, Kathy White, et al.. (2021). Engineered Hypoimmune Allogeneic CAR T Cells Exhibit Innate and Adaptive Immune Evasion Even after Sensitization in Humanized Mice and Retain Potent Anti-Tumor Activity. Blood. 138(Supplement 1). 1690–1690. 3 indexed citations
9.
Hu, Xiaomeng, Mo A. Dao, Kathy White, et al.. (2021). Abstract LB144: Overexpression of CD47 protects hypoimmune CAR T cells from innate immune cell killing. Cancer Research. 81(13_Supplement). LB144–LB144. 5 indexed citations
10.
Lamagna, Chrystelle, Meagan Chan, Chi Young, et al.. (2020). OP0046 TARGETING IRAK1 AND 4 SIGNALING WITH R835, A NOVEL ORAL SMALL MOLECULE INHIBITOR: A POTENTIAL NEW TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS. Annals of the Rheumatic Diseases. 79. 30–30. 5 indexed citations
11.
Lamagna, Chrystelle, Meagan Chan, Chi Young, et al.. (2020). FRI0016 R835, A NOVEL IRAK1/4 DUAL INHIBITOR IN CLINICAL DEVELOPMENT, BLOCKS TOLL-LIKE RECEPTOR 4 (TLR4) SIGNALING IN HUMAN AND MOUSE. Annals of the Rheumatic Diseases. 79. 579–579. 4 indexed citations
12.
Lamagna, Chrystelle, Meagan Chan, Sothy Yi, et al.. (2020). OP0133 PRECLINICAL EFFICACY OF R835, A NOVEL IRAK1/4 DUAL INHIBITOR, IN RODENT MODELS OF JOINT INFLAMMATION. Annals of the Rheumatic Diseases. 79. 86–86. 4 indexed citations
13.
Markovtsov, Vadim, Chrystelle Lamagna, Meagan Chan, et al.. (2016). Abstract 346: Potential role for R191, potent and selective IRAK4 kinase inhibitor, in treatment of hematologic malignancies. Cancer Research. 76(14_Supplement). 346–346. 3 indexed citations
14.
Holland, Sacha J., Sothy Yi, Chi Young, et al.. (2016). Abstract 4869: Small molecule inhibitors of the anti-inflammatory TAM receptor MerTK. Cancer Research. 76(14_Supplement). 4869–4869.
15.
Taylor, Vanessa, Chi Young, Linda Ste. Marie, et al.. (2012). R256 Is A Potent And Selective IL-13/4 Receptor Signaling Inhibitor That Reduces Inflammation In A Mouse Model Of Chronic Asthma. A2843–A2843. 2 indexed citations
16.
Young, Chi. (2004). The role of nonsteroidal antiinflammatory drugs in cancer chemoprevention. Drugs of the Future. 29(5). 467–467. 1 indexed citations
17.
Masuda, Esteban S., Ying Luo, Chi Young, et al.. (2000). Rab37 is a novel mast cell specific GTPase localized to secretory granules. FEBS Letters. 470(1). 61–64. 63 indexed citations
18.
Young, Chi, Robert Burrows, Jonathan L. Katz, & H. L. C. Beynon. (1999). Hypercalcaemia in sarcoidosis. The Lancet. 353(9150). 374–374. 15 indexed citations
19.
Berson, Amy E., Chi Young, Sherie L. Morrison, et al.. (1999). Identification and Characterization of a Myristylated and Palmitylated Serine/Threonine Protein Kinase. Biochemical and Biophysical Research Communications. 259(3). 533–538. 24 indexed citations
20.
Helfgott, Simon M., Raphael I. Kieval, F. C. Breedveld, et al.. (1988). Detection of arthritogenic factor in adjuvant arthritis.. The Journal of Immunology. 140(6). 1838–1843. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026